<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02868086</url>
  </required_header>
  <id_info>
    <org_study_id>MMT_2015_42</org_study_id>
    <nct_id>NCT02868086</nct_id>
  </id_info>
  <brief_title>The Impact of Two Strategies in the Monitoring of Exudative ARMD on the Visual Acuity (by OCT B Scan or OCT Angiography)</brief_title>
  <acronym>REPERM-OCT</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <brief_summary>
    <textblock>
      The treatment of neovascular age-related macular degeneration (ARMD) is a major issue of&#xD;
      public health. The therapeutic arsenal has widely grown throughout the years with the&#xD;
      emergence of intra-vitreous anti-angiogenic treatments, under different surveillance&#xD;
      protocols. The &quot;PRN&quot; surveillance (pro re nata: an on-demand treatment with monthly&#xD;
      follow-up) allows a faster re-injection in case of neovascular relapse in order to maintain&#xD;
      the best visual acuity. This therapeutic protocol is guided by the sub-retinal neovascular&#xD;
      signs of activity. The monitoring is done during common practice via OCT B scans showing&#xD;
      indirect signs of neovascular activity (exudation signs). OCT retinal imaging has been&#xD;
      recently enriched with new programs allowing the visualization of sub-retinal neovessels&#xD;
      without the use dyes (OCT angiography). The OCT angiography is automatically done by a&#xD;
      program using standard OCT sections. During the monitoring of a patient using the OCT A, the&#xD;
      signs of renewed neovascular activity are represented by an &quot;arterialization&quot; or the&#xD;
      development of an arteriole network of the neovessel with the reappearance of a hyper&#xD;
      reflective flow after a neovascular regressive phase. Indeed, the visualization of neovessels&#xD;
      during the monitoring by Angio-OCT may lead to therapeutical modifications (anticipation of&#xD;
      the injections). Knowing that the injection time-table of ARMD patients treated with&#xD;
      anti-angiogenics is determined by sub-retinal neovascular signs of activity. This activity is&#xD;
      evaluated during routine clinical practice by very specific signs, observable on OCT B scans.&#xD;
      The hypothesis of this study is that the search of activity sins on the Angio-OCT, a new&#xD;
      technic of image analysis performed on the OCT, may modify this injection time-table, with an&#xD;
      impact of the patient's visual acuity.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 21, 2016</start_date>
  <completion_date type="Actual">April 15, 2021</completion_date>
  <primary_completion_date type="Actual">November 20, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual acuity improvement or stabilization</measure>
    <time_frame>Between the inclusion and 1 year of follow-up</time_frame>
    <description>Proportion of patients with visual acuity improvement or stabilization</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Tested patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients treated with anti-angiogenics for ARMD : monitoring using optical coherence tomography angiography</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control patients</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients treated with anti-angiogenics for ARMD : monitoring during common practice via optical coherence tomography B scans</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OCT B-scans</intervention_name>
    <arm_group_label>Control patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OCT angiography</intervention_name>
    <arm_group_label>Tested patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patient â‰¥ 50 years old&#xD;
&#xD;
          -  with exudative ARMD,&#xD;
&#xD;
          -  treated with intra-vitreous anti-angiogenics following a PRN protocol (pro re nata)&#xD;
&#xD;
          -  Absence of atrophy of the central pigment epithelium&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Opposition to participate in this research&#xD;
&#xD;
          -  Persons enjoying legal protection measure&#xD;
&#xD;
          -  Lack of affiliation to social security and universal health coverage&#xD;
&#xD;
          -  Pregnant or lactating&#xD;
&#xD;
          -  Another cause of Choroidal neovascularization&#xD;
&#xD;
          -  Unbalanced glaucoma&#xD;
&#xD;
          -  Eye surgery less than 3 months on the studied eye&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fondation Ophtalmologique A. de Rotchschild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>August 11, 2016</study_first_submitted>
  <study_first_submitted_qc>August 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2016</study_first_posted>
  <last_update_submitted>May 21, 2021</last_update_submitted>
  <last_update_submitted_qc>May 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Age-related macular degeneration</keyword>
  <keyword>Optical coherence tomography angiography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

